In response to the escalating demand for precision therapies, ADCs have emerged as a promising and efficacious treatment modality, which integrate the specificity of monoclonal antibodies with potent cytotoxic drugs, delivering a highly targeted approach to cancer therapy. Creative Biolabs, specializing in antibody discovery and synthetic chemistry, is unwavering in its commitment to furnishing cutting-edge ADC development solutions to the pharmaceutical industry.
As a part of their expanded ADC services, Creative Biolabs has introduced the
antibody-oligonucleotide conjugate (AOC) development program. This pioneering service harnesses the unique properties of oligonucleotides and antibodies to reach enhanced therapeutic potential. By conjugating oligonucleotides with antibodies, the AOCs constructed can trigger complex biological mechanisms ranging from immune responses to cell differentiation, apoptosis, and protein expression, and thereby apply to multiple academic and industrial fields.
The selection of a payload or cytotoxic drug is pivotal in ensuring the safety and efficacy of ADCs. Creative Biolabs offers a comprehensive array of highly potent ADC toxins targeting different cellular pathways, encompassing microtubule assembly and dynamics (microtubule toxins), DNA biochemistry and structure (DNA toxins), and gene transcription (transcription toxins). Each toxin undergoes meticulous selection and evaluation to align with the specific requirements of individual ADC projects.
Furthermore, Creative Biolabs acknowledges the critical role of ADC linkers in determining the stability and controlled release of cytotoxic drugs and has launched a diverse spectrum of chemical linkers with distinct properties, including cleavable linkers and non-cleavable linkers. These linkers, with over 95% purity, are designed to facilitate the conjugation of toxins to antibodies while dictating the controlled release of the cytotoxic payload, aiming to assist in the development of ADCs with superior chemical and serum stability.
"The expansion of our ADC services is designed to address the pressing needs of our clients in the field of targeted cancer therapy," affirmed a scientist at Creative Biolabs. "We are thrilled to present these innovative solutions, which will undoubtedly contribute to the development of novel ADCs with enhanced efficacy and safety profiles."